ArticleActa neurochirurgica2026
Half-dose ticagrelor versus clopidogrel dual antiplatelet therapy in flow diverter-treated intracranial aneurysms: analysis of platelet reactivity and perioperative safety outcomes.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThe safety and efficacy of half-dose ticagrelor (45 mg twice daily) dual antiplatelet therapy (DAPT) for flow diverter (FD) treatment of intracranial aneurysm (IA), particularly in Chinese patients and with PED (Pipeline embolization device) Flex Shield, remains uncertain. This study assessed whether this regimen maintains efficacy while improving safety, including its applicability to PED Flex Shield.
methodsThis single-center retrospective study analyzed consecutive IA patients undergoing FD treatment between 2019-2024, comparing standard-dose clopidogrel (75 mg daily) plus aspirin (100 mg daily) with half-dose ticagrelor (45 mg twice daily) plus aspirin (100 mg daily). Outcomes included adenosine diphosphate-induced maximal platelet aggregation (ADPi-MPA) measured by light transmittance aggregometry, perioperative complications within 30 days post-procedure, and analysis of factors influencing ADPi-MPA levels.
resultsThe study included 405 IA patients (half-dose ticagrelor = 224, standard-dose clopidogrel = 181). The half-dose ticagrelor group demonstrated significantly lower ADPi-MPA (26.00 [17.45, 34.25] vs 37.70 [29.50, 43.60], P < 0.001), with comparable ischemic (3.1% vs 5.5%, P = 0.114) and hemorrhagic (2.1% vs 1.2%, P = 0.689) event rates. No significant differences in perioperative complications were found between FD types (PED/PED Flex/TED vs PED Flex Shield) when using the half-dose ticagrelor regimen (all P > 0.05). Similarly, complication rates were comparable between the two DAPT regimens across both FD subgroups (all P > 0.05).
conclusionThis study demonstrates that half-dose ticagrelor DAPT achieves significantly lower platelet reactivity (ADPi-MPA) compared to standard-dose clopidogrel, with no statistically significant differences in ischemic or hemorrhagic complication rates observed among FD-treated IA patients. Importantly, the half-dose regimen shows consistent performance across different FD devices (including PED Flex Shield) without compromising perioperative safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.